VivoSeq
Ophthalmology

Diabetic Macular Edema

136

Pipeline Programs↗

44

Active Trials↗

47

Companies Involved↗

Diabetic Macular Edema is a highly competitive landscape with 136 programs across 47 companies. The most active players are Eleven Biotherapeutics, BioCryst Pharmaceuticals, iCo Therapeutics Inc.. 13 therapies are approved with 27 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

76/100

Pipeline Velocity

39/100

Mech. Concentration

14/100

Completion Rate

83/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eleven Biotherapeutics

1 program

Phase 1B

BioCryst Pharmaceuticals

1 program

Phase 1I

iCo Therapeutics Inc.

1 program

Phase 1A

AskGene Pharma, Inc.

1 program

Phase 1S

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

1 program

Phase 1H

Horizon Therapeutics Ireland DAC

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical15

Faricimab

Roche

Methotrexate

Alnylam Pharmaceuticals

Anti-VEGF

Pfizer

Low Dose BI 3812465

Boehringer Ingelheim

Medium Dose BI 3812465

Boehringer Ingelheim

Phase 131

Infliximab

Organon and Co

Teprotumumab

Horizon Therapeutics Ireland DAC

Bromfenac

Bausch Health Americas, Inc.

Minocycline

Triax

Octreotide

Sun Pharma

Phase 250

Pegaptanib Sodium

Pfizer

Dapagliflozin

AstraZeneca

Danazol

Sanofi

BAY 1841788

Bayer

Aliskiren

Tibotec Pharmaceuticals, Ireland

Phase 327

Conbercept

Chengdu Kanghong Biotech Co., Ltd.

Brolucizumab

Novartis

Bevacizumab

Bio-Thera Solutions

Metformin

EMD Serono

Triamcinolone Acetonide

Bausch Health Americas, Inc.

Approved13

Spironolactone

Pfizer

Potassium Chloride

Novartis

Dexamethasone

Aspen Global Incorporated

Glimepiride

Sanofi

Triamcinolone

Bassett Healthcare

Analysis

Modality Breakdown

84%

Small molecule

139 of 166 classified programs — the dominant modality here.

16%ALL OTHERSMonoclonal antibody1811%Protein / enzyme85%Peptide1<1%

Small molecule leads; the ring shows all 166 classified programs, each share of the total. Modality classified for 96% of 181 pipeline programs.

Analysis

Trial Status

323

clinical trials

Completed194 · 60%
Unknown status46 · 14%
Withdrawn20 · 6%
Terminated19 · 6%
Recruiting19 · 6%
Active, not recruiting17 · 5%
Other8 · 2%

Clinical Trials

Trial Activity

323 trials

Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
Recruiting·OOcugen·Phase 1·NCT05802329·24 enrolled
A Study of Avoralstat In Participants With Diabetic Macular Edema
Recruiting·BBioCryst Pharmaceuticals·Phase 1·NCT07228559·9 enrolled
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Recruiting·IIncepta Pharmaceuticals Ltd·Phase 3·NCT06305416·70 enrolled
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
Recruiting·SSierra Eye Associates·Phase 2·NCT06942520·18 enrolled
Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT
Recruiting·ZZhongshan Ophthalmic Center, Sun Yat-sen University·N/A·NCT06610747·308 enrolled
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
Recruiting·RRetina Consultants of Orange County·Phase 4·NCT06662994·15 enrolled
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
Recruiting·—·Phase 1·NCT06781255·5 enrolled
Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema
Recruiting·TTianjin Medical University Eye Hospital·N/A·NCT05728476·102 enrolled
Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema
Recruiting·—·Phase 2·NCT03161652·120 enrolled
Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema
Recruiting·RRemeGen Co., Ltd.·Phase 3·NCT05885503·316 enrolled
A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）
Recruiting·IInnovent Biologics Technology Limited (Shanghai R&D Center)·Phase 2·NCT06908876·150 enrolled
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
Recruiting·Roche logoRoche·Phase 1·NCT07425522·93 enrolled
Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema
Recruiting·—·Phase 2·NCT06845163·56 enrolled
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
Recruiting·EEclipse Life Sciences, Inc.·Phase 1/2·NCT06536491·75 enrolled
Kamuvudine-9 (K9) in Diabetic Macular Edema
Recruiting·—·Phase 1/2·NCT07458061·10 enrolled
Page 1 of 22

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)